APA (7th ed.) Citation

Shui, L., Cheng, K., Li, X., Shui, P., Zhou, X., Li, J., . . . Cao, D. (2020). Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma. BMC Cancer, 20(1), 1. https://doi.org/10.1186/s12885-020-07126-3

Chicago Style (17th ed.) Citation

Shui, Lin, Ke Cheng, Xiaofen Li, Pixian Shui, Xiaohan Zhou, Jian Li, Cheng Yi, and Dan Cao. "Study Protocol for an Open-label, Single-arm, Phase Ib/II Study of Combination of Toripalimab, Nab-paclitaxel, and Gemcitabine as the First-line Treatment for Patients with Unresectable Pancreatic Ductal Adenocarcinoma." BMC Cancer 20, no. 1 (2020): 1. https://doi.org/10.1186/s12885-020-07126-3.

MLA (9th ed.) Citation

Shui, Lin, et al. "Study Protocol for an Open-label, Single-arm, Phase Ib/II Study of Combination of Toripalimab, Nab-paclitaxel, and Gemcitabine as the First-line Treatment for Patients with Unresectable Pancreatic Ductal Adenocarcinoma." BMC Cancer, vol. 20, no. 1, 2020, p. 1, https://doi.org/10.1186/s12885-020-07126-3.